Summary
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.
Eligibility
- Independent School Districts
- Public and Indian Housing Authorities
- Other
- Nonprofits Non Higher Education Without 501c3
- Native American Tribal Governments Federally Recognized
- Private Institutions of Higher Education
- County Governments
- Native American Tribal Organizations Other Than Federally Recognized Tribal Governments
- Special District Governments
- Nonprofits Having A 501(c)(3) Status With the Irs Other Than Institutions of Higher Education
- For Profit Organizations Other Than Small Businesses
- City Or Township Governments
- Small Businesses
- State Governments
- Public and State Institutions of Higher Education
Funding categories
- Health
Official source and attribution
This directory republishes federal opportunity information sourced from Simpler.Grants.gov and Grants.gov. Local Business Ranks is not affiliated with or endorsed by the federal government. Always rely on the official opportunity record for application requirements and changes.
Open the official federal record